Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines of therapy. The drug was associated with myelosuppression and gastrointestinal toxicity; interstitia...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine Jg. 382; H. 7; S. 610 - 621
Hauptverfasser:	Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Massachusetts Medical Society 13.02.2020
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Body weight Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Confidence intervals Consolidation Chemotherapy Cytotoxicity DNA topoisomerase Drug dosages Epidermal growth factor ErbB-2 protein Female Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunotherapy Intention to Treat Analysis Kaplan-Meier Estimate Lung diseases Lung Diseases, Interstitial - chemically induced Metastases Metastasis Middle Aged Monoclonal antibodies Myelosuppression Nausea Patients Progression-Free Survival Receptor, ErbB-2 - analysis Receptor, ErbB-2 - antagonists & inhibitors Targeted cancer therapy Trastuzumab Tumors
ISSN:	0028-4793, 1533-4406, 1533-4406
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines of therapy. The drug was associated with myelosuppression and gastrointestinal toxicity; interstitial lung disease was reported in 13.6% of the patients.
AbstractList	BackgroundTrastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.MethodsIn this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.ResultsOverall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).ConclusionsTrastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.) In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines of therapy. The drug was associated with myelosuppression and gastrointestinal toxicity; interstitial lung disease was reported in 13.6% of the patients. Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.). Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.BACKGROUNDTrastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.METHODSIn this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).RESULTSOverall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).CONCLUSIONSTrastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
Author	Lee, Keun Seok Lee, Caleb Kim, Sung-Bae Modi, Shanu Ito, Yoshinori Denduluri, Neelima Krop, Ian Tamura, Kenji Perrin, Christophe Shahidi, Javad Tokunaga, Eriko Chen, Shuquan Saura, Cristina Park, Yeon Hee Aogi, Kenjiro Zhang, Lin Tsurutani, Junji Andre, Fabrice Iwata, Hiroji Cortes, Javier Hurvitz, Sara A Yamashita, Toshinari Sohn, Joohyuk Im, Seock-Ah Yver, Antoine
Author_xml	– sequence: 1 givenname: Shanu surname: Modi fullname: Modi, Shanu organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 2 givenname: Cristina surname: Saura fullname: Saura, Cristina organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 3 givenname: Toshinari surname: Yamashita fullname: Yamashita, Toshinari organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 4 givenname: Yeon Hee surname: Park fullname: Park, Yeon Hee organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 5 givenname: Sung-Bae surname: Kim fullname: Kim, Sung-Bae organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 6 givenname: Kenji surname: Tamura fullname: Tamura, Kenji organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 7 givenname: Fabrice surname: Andre fullname: Andre, Fabrice organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 8 givenname: Hiroji surname: Iwata fullname: Iwata, Hiroji organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 9 givenname: Yoshinori surname: Ito fullname: Ito, Yoshinori organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 10 givenname: Junji surname: Tsurutani fullname: Tsurutani, Junji organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 11 givenname: Joohyuk surname: Sohn fullname: Sohn, Joohyuk organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 12 givenname: Neelima surname: Denduluri fullname: Denduluri, Neelima organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 13 givenname: Christophe surname: Perrin fullname: Perrin, Christophe organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 14 givenname: Kenjiro surname: Aogi fullname: Aogi, Kenjiro organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 15 givenname: Eriko surname: Tokunaga fullname: Tokunaga, Eriko organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 16 givenname: Seock-Ah surname: Im fullname: Im, Seock-Ah organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 17 givenname: Keun Seok surname: Lee fullname: Lee, Keun Seok organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 18 givenname: Sara A surname: Hurvitz fullname: Hurvitz, Sara A organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 19 givenname: Javier surname: Cortes fullname: Cortes, Javier organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 20 givenname: Caleb surname: Lee fullname: Lee, Caleb organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 21 givenname: Shuquan surname: Chen fullname: Chen, Shuquan organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 22 givenname: Lin surname: Zhang fullname: Zhang, Lin organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 23 givenname: Javad surname: Shahidi fullname: Shahidi, Javad organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 24 givenname: Antoine surname: Yver fullname: Yver, Antoine organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.) – sequence: 25 givenname: Ian surname: Krop fullname: Krop, Ian organization: From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) — all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) — all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) — both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles–Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana–Farber Cancer Institute, Boston (I.K.)
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31825192$$D View this record in MEDLINE/PubMed
BookMark	eNp1kd1LHDEUxUOx1NX20VcZKAVfpuZzMvNSsNttt0VbKetzyGTuaJaZxCaZRfvXN7JaVPC-BO793cM5uXtox3kHCB0Q_JFgUR3_XPw485o0hAuCX6EZEYyVnONqB80wpnXJZcN20V6Ma5yL8OYN2mWkpoI0dIaWq6Bjmv5Oo26LLxCmmwRGu8K64jzAxvopDrfFKoBO0BXLxW9anvtok91A8Tl3Yyrm2hkIb9HrXg8R3t2_--ji62I1X5anv759n5-clkYQkkrRgW6M7DtpDGgKTS84kzXBkvGcp6VMtjUXzGBDMRM5U9dQ2WpOqraXVLN99Gmrez21I3QGXAp6UNfBjjrcKq-tejpx9kpd-o2SXNSVJFng6F4g-D8TxKRGGw0Mg3aQ0yrKKG-IlIRm9P0zdO2n4HK8TAlOKyx5nanDx47-W3n45AywLWCCjzFAr4xNOll_Z9AOimB1d0r15JR5q3y29SD8Ev9hy49jVA7W4wvcPzDgqgU
CitedBy_id	crossref_primary_10_1111_cas_70181 crossref_primary_10_1007_s11060_022_04132_2 crossref_primary_10_1200_EDBK_281103 crossref_primary_10_1200_EDBK_281107 crossref_primary_10_1016_j_jmb_2025_169401 crossref_primary_10_1038_s41598_024_82137_9 crossref_primary_10_1016_j_currproblcancer_2022_100892 crossref_primary_10_3390_cancers15133305 crossref_primary_10_1016_j_cpccr_2023_100242 crossref_primary_10_3389_fonc_2025_1565872 crossref_primary_10_2147_BCTT_S288344 crossref_primary_10_7759_cureus_79926 crossref_primary_10_3390_life12060829 crossref_primary_10_3390_cancers13051052 crossref_primary_10_1093_neuonc_noaa118 crossref_primary_10_1016_j_critrevonc_2022_103758 crossref_primary_10_1080_14740338_2024_2439510 crossref_primary_10_1080_0284186X_2023_2260943 crossref_primary_10_1016_j_annonc_2023_12_001 crossref_primary_10_3390_medsci8010018 crossref_primary_10_1002_cam4_4052 crossref_primary_10_1007_s11096_023_01673_y crossref_primary_10_1016_j_pharmthera_2022_108108 crossref_primary_10_1186_s12885_023_11735_z crossref_primary_10_3390_cancers15051385 crossref_primary_10_1002_cpt_2334 crossref_primary_10_1177_17588359231152842 crossref_primary_10_2217_fon_2021_0546 crossref_primary_10_3389_fphar_2024_1304502 crossref_primary_10_3389_fonc_2022_1048781 crossref_primary_10_1007_s13139_024_00843_8 crossref_primary_10_1016_S1470_2045_21_00301_6 crossref_primary_10_1093_ehjci_jeac106 crossref_primary_10_1016_j_pathol_2025_02_003 crossref_primary_10_3390_cancers14153718 crossref_primary_10_1002_ijc_32937 crossref_primary_10_1097_CM9_0000000000001932 crossref_primary_10_1055_a_1904_6100 crossref_primary_10_1097_CCO_0000000000001087 crossref_primary_10_1016_j_critrevonc_2023_104090 crossref_primary_10_3390_pharmaceutics15041242 crossref_primary_10_1097_CAD_0000000000001613 crossref_primary_10_3390_jcm12237325 crossref_primary_10_3390_pharmaceutics13091446 crossref_primary_10_1186_s12935_022_02679_8 crossref_primary_10_3390_pharmaceutics16091146 crossref_primary_10_1007_s13193_024_01935_9 crossref_primary_10_1158_1078_0432_CCR_20_0844 crossref_primary_10_1007_s10549_022_06832_9 crossref_primary_10_1038_s41467_020_15885_7 crossref_primary_10_3390_cancers14010196 crossref_primary_10_1016_j_ab_2024_115530 crossref_primary_10_1200_EDBK_280463 crossref_primary_10_1177_20420986231224227 crossref_primary_10_3389_fonc_2022_819818 crossref_primary_10_1016_j_fmre_2024_02_021 crossref_primary_10_3390_cancers14235940 crossref_primary_10_1111_1759_7714_14858 crossref_primary_10_1111_jcpt_13777 crossref_primary_10_3390_cancers13051047 crossref_primary_10_1016_j_drup_2024_101078 crossref_primary_10_1016_j_modpat_2022_100087 crossref_primary_10_1016_j_annonc_2025_07_015 crossref_primary_10_1186_s13058_023_01743_z crossref_primary_10_1016_j_clbc_2021_02_001 crossref_primary_10_1038_s41523_021_00294_w crossref_primary_10_1158_1078_0432_CCR_22_1138 crossref_primary_10_1200_EDBK_281381 crossref_primary_10_3390_cancers17061032 crossref_primary_10_1158_1078_0432_CCR_22_0283 crossref_primary_10_1097_CCO_0000000000001064 crossref_primary_10_1177_1060028021998320 crossref_primary_10_1159_000531164 crossref_primary_10_2217_fon_2019_0719 crossref_primary_10_1007_s12672_023_00660_z crossref_primary_10_1007_s11095_022_03263_5 crossref_primary_10_1053_j_semnuclmed_2025_08_002 crossref_primary_10_1158_1078_0432_CCR_24_2771 crossref_primary_10_1016_j_annonc_2025_07_001 crossref_primary_10_3390_jcm13174995 crossref_primary_10_3390_cancers16020466 crossref_primary_10_1016_j_labinv_2025_104233 crossref_primary_10_1186_s13058_021_01459_y crossref_primary_10_1097_CAD_0000000000001625 crossref_primary_10_1158_2159_8290_CD_21_0715 crossref_primary_10_1038_s41523_021_00326_5 crossref_primary_10_1016_j_ejmech_2020_112667 crossref_primary_10_1080_14740338_2023_2204228 crossref_primary_10_2217_fon_2021_0742 crossref_primary_10_3390_cancers13194894 crossref_primary_10_1007_s12282_025_01670_1 crossref_primary_10_1016_S0007_4551_21_00632_9 crossref_primary_10_1007_s12609_024_00558_x crossref_primary_10_1186_s13014_023_02293_6 crossref_primary_10_1186_s13045_025_01704_3 crossref_primary_10_1016_j_breast_2021_09_011 crossref_primary_10_3390_pharmaceutics16070890 crossref_primary_10_1056_NEJMoa2115022 crossref_primary_10_3389_fonc_2024_1469438 crossref_primary_10_1007_s00761_021_01060_0 crossref_primary_10_1021_jacs_3c10185 crossref_primary_10_1007_s12272_023_01447_0 crossref_primary_10_1016_j_bbcan_2025_189369 crossref_primary_10_1016_j_clbc_2023_05_003 crossref_primary_10_3390_cancers13051078 crossref_primary_10_1002_bdd_2371 crossref_primary_10_3892_or_2024_8854 crossref_primary_10_1038_s10038_021_00962_6 crossref_primary_10_3390_cancers15041130 crossref_primary_10_3390_cancers17111823 crossref_primary_10_1007_s00428_022_03378_5 crossref_primary_10_1200_EDBK_431766 crossref_primary_10_1097_GCO_0000000000000762 crossref_primary_10_3390_cancers17142307 crossref_primary_10_3389_fonc_2024_1413674 crossref_primary_10_1016_j_ijpharm_2024_124211 crossref_primary_10_1111_cas_16234 crossref_primary_10_3389_fgene_2023_1156095 crossref_primary_10_1158_2159_8290_CD_21_0936 crossref_primary_10_1038_s41467_023_44533_z crossref_primary_10_1002_cac2_12387 crossref_primary_10_3390_diagnostics11020252 crossref_primary_10_1002_cpt_2757 crossref_primary_10_3390_cancers17152522 crossref_primary_10_1016_j_breast_2022_03_013 crossref_primary_10_1016_j_hoc_2023_02_004 crossref_primary_10_1002_14651858_CD014872_pub2 crossref_primary_10_3390_ijms25031941 crossref_primary_10_1177_17588359221086916 crossref_primary_10_1038_s41582_020_0391_x crossref_primary_10_1002_mco2_97 crossref_primary_10_1016_j_cbi_2022_110108 crossref_primary_10_1038_s41571_025_01008_y crossref_primary_10_3390_cancers14235754 crossref_primary_10_3389_fphar_2023_1183514 crossref_primary_10_1016_j_clbc_2023_03_013 crossref_primary_10_1177_17588359241277647 crossref_primary_10_1002_cai2_97 crossref_primary_10_1016_S1470_2045_24_00380_2 crossref_primary_10_1158_2159_8290_CD_21_0124 crossref_primary_10_3389_fonc_2022_811919 crossref_primary_10_1177_10732748241250189 crossref_primary_10_1159_000533787 crossref_primary_10_1016_j_bulcan_2023_04_013 crossref_primary_10_3389_fonc_2024_1374547 crossref_primary_10_1007_s00761_020_00766_x crossref_primary_10_1007_s10549_021_06469_0 crossref_primary_10_1007_s10120_021_01196_3 crossref_primary_10_1186_s40164_024_00493_8 crossref_primary_10_1007_s40290_023_00505_8 crossref_primary_10_1080_14712598_2020_1802423 crossref_primary_10_1038_s41598_020_64518_y crossref_primary_10_1039_D1SC02973H crossref_primary_10_1007_s10549_021_06423_0 crossref_primary_10_3390_cancers15092508 crossref_primary_10_1007_s11060_022_03977_x crossref_primary_10_1007_s12254_021_00709_1 crossref_primary_10_26442_18151434_2025_1_202822 crossref_primary_10_1002_cncr_35475 crossref_primary_10_2217_fon_2022_1040 crossref_primary_10_1016_j_modpat_2022_100009 crossref_primary_10_1002_onco_13878 crossref_primary_10_1007_s11912_022_01234_y crossref_primary_10_3390_molecules25204764 crossref_primary_10_1158_1078_0432_CCR_20_2878 crossref_primary_10_1007_s10549_021_06280_x crossref_primary_10_1016_j_clbc_2020_08_006 crossref_primary_10_1007_s40487_021_00178_w crossref_primary_10_1080_14712598_2021_1936494 crossref_primary_10_1177_11795549231202463 crossref_primary_10_1007_s11864_024_01195_3 crossref_primary_10_3390_cancers15184522 crossref_primary_10_1016_j_critrevonc_2024_104305 crossref_primary_10_1172_JCI166384 crossref_primary_10_2147_JMDH_S422391 crossref_primary_10_3390_pharmaceutics15082160 crossref_primary_10_1016_j_oraloncology_2023_106566 crossref_primary_10_1177_17588359221079123 crossref_primary_10_3390_cancers14020391 crossref_primary_10_1016_j_dmpk_2024_101001 crossref_primary_10_1007_s00330_023_10198_x crossref_primary_10_1055_a_1111_8775 crossref_primary_10_1200_EDBK_279465 crossref_primary_10_3389_fonc_2024_1338661 crossref_primary_10_1038_s41523_025_00800_4 crossref_primary_10_3390_ph16040614 crossref_primary_10_1097_GCO_0000000000000930 crossref_primary_10_1007_s40261_021_01070_1 crossref_primary_10_1016_j_critrevonc_2024_104355 crossref_primary_10_1016_j_semcancer_2021_03_031 crossref_primary_10_2147_LCTT_S307324 crossref_primary_10_1080_14737140_2020_1782201 crossref_primary_10_3390_ijtm3030022 crossref_primary_10_1016_j_breast_2022_10_010 crossref_primary_10_1111_cas_14686 crossref_primary_10_1007_s10147_025_02800_7 crossref_primary_10_1016_j_eururo_2022_09_004 crossref_primary_10_3389_fphar_2021_741451 crossref_primary_10_3390_biomedicines13051153 crossref_primary_10_1007_s40259_021_00472_z crossref_primary_10_3389_fonc_2025_1645438 crossref_primary_10_3322_caac_21777 crossref_primary_10_1016_j_breast_2022_10_016 crossref_primary_10_1016_j_modpat_2022_100032 crossref_primary_10_3390_cancers16010023 crossref_primary_10_1016_S0140_6736_22_02420_5 crossref_primary_10_1002_cai2_46 crossref_primary_10_1016_j_yao_2021_02_023 crossref_primary_10_3389_fmolb_2022_847835 crossref_primary_10_1158_1078_0432_CCR_22_0456 crossref_primary_10_1016_j_cpccr_2020_100034 crossref_primary_10_1093_oncolo_oyae177 crossref_primary_10_3389_fonc_2025_1633448 crossref_primary_10_1016_j_dld_2022_05_013 crossref_primary_10_3390_cancers14163996 crossref_primary_10_1200_EDBK_390094 crossref_primary_10_2217_fon_2021_0550 crossref_primary_10_1038_s41523_025_00748_5 crossref_primary_10_3390_cells11030575 crossref_primary_10_1056_NEJMoa2203690 crossref_primary_10_1158_1078_0432_CCR_22_2630 crossref_primary_10_3390_ijms22094774 crossref_primary_10_1093_eurheartj_ehae161 crossref_primary_10_1371_journal_pone_0257976 crossref_primary_10_1007_s10555_022_10021_x crossref_primary_10_1016_j_semcancer_2021_02_004 crossref_primary_10_1186_s12885_022_10015_6 crossref_primary_10_1007_s00228_024_03644_2 crossref_primary_10_1080_14712598_2021_1880562 crossref_primary_10_1177_15330338251328522 crossref_primary_10_1016_j_hoc_2021_08_004 crossref_primary_10_3390_pharmaceutics14112519 crossref_primary_10_3390_cancers13122922 crossref_primary_10_1016_j_hoc_2021_08_009 crossref_primary_10_1016_j_jclinepi_2022_03_011 crossref_primary_10_1055_a_1724_9569 crossref_primary_10_3389_fonc_2021_780379 crossref_primary_10_1177_10732748221106267 crossref_primary_10_3390_cancers13122927 crossref_primary_10_1016_j_critrevonc_2025_104624 crossref_primary_10_3892_or_2022_8366 crossref_primary_10_1159_000531579 crossref_primary_10_3389_fonc_2025_1551415 crossref_primary_10_1007_s12325_023_02538_6 crossref_primary_10_3389_fonc_2021_715554 crossref_primary_10_2217_fon_2021_0333 crossref_primary_10_1016_j_jcis_2025_138422 crossref_primary_10_1371_journal_pone_0326691 crossref_primary_10_1056_NEJMc2202305 crossref_primary_10_1007_s12282_022_01383_9 crossref_primary_10_1080_14737140_2023_2208350 crossref_primary_10_3390_cancers14010154 crossref_primary_10_3389_fonc_2023_1244781 crossref_primary_10_3390_ijms24119674 crossref_primary_10_1007_s12254_020_00632_x crossref_primary_10_1055_a_2074_0125 crossref_primary_10_2147_CMAR_S330829 crossref_primary_10_3389_fonc_2021_699333 crossref_primary_10_1016_j_breast_2024_103756 crossref_primary_10_1158_1078_0432_CCR_20_4557 crossref_primary_10_1002_advs_202400203 crossref_primary_10_1007_s12672_024_01705_7 crossref_primary_10_1016_j_bbcan_2021_188605 crossref_primary_10_1016_j_breast_2022_01_002 crossref_primary_10_1016_j_mtbio_2025_101517 crossref_primary_10_1177_10915818241306039 crossref_primary_10_64013_bbasr_v2025i1_104 crossref_primary_10_1002_rcr2_928 crossref_primary_10_1136_jim_2021_002298 crossref_primary_10_1080_14737140_2021_1857243 crossref_primary_10_1186_s13058_025_02094_7 crossref_primary_10_1007_s00210_025_04401_7 crossref_primary_10_1093_jjco_hyad036 crossref_primary_10_1093_oncolo_oyad185 crossref_primary_10_1016_j_clbc_2020_11_014 crossref_primary_10_1200_OP_21_00216 crossref_primary_10_1159_000542761 crossref_primary_10_1016_j_pathol_2023_10_022 crossref_primary_10_1016_j_urolonc_2021_10_002 crossref_primary_10_1055_a_1286_2917 crossref_primary_10_1007_s41669_023_00405_2 crossref_primary_10_1097_CEJ_0000000000000781 crossref_primary_10_3389_fonc_2022_854364 crossref_primary_10_3390_life14081040 crossref_primary_10_1080_1120009X_2024_2366683 crossref_primary_10_1089_mab_2021_0025 crossref_primary_10_1038_s41573_025_01147_y crossref_primary_10_1016_j_breast_2024_103853 crossref_primary_10_3390_ijms23105476 crossref_primary_10_1016_j_bmc_2024_117773 crossref_primary_10_1177_17588359241311379 crossref_primary_10_3390_cancers13205198 crossref_primary_10_1093_jjco_hyad026 crossref_primary_10_1097_CMR_0000000000000702 crossref_primary_10_1016_j_ctrv_2022_102500 crossref_primary_10_3390_jcm12103391 crossref_primary_10_1007_s10549_021_06329_x crossref_primary_10_1007_s10549_021_06427_w crossref_primary_10_3390_pharmaceutics16040445 crossref_primary_10_1007_s10549_021_06449_4 crossref_primary_10_3390_cancers16061156 crossref_primary_10_1038_s43018_021_00229_1 crossref_primary_10_1097_CCO_0000000000000670 crossref_primary_10_1016_j_annonc_2020_09_004 crossref_primary_10_3390_antib9030032 crossref_primary_10_1016_j_cell_2022_05_029 crossref_primary_10_1038_s41467_020_19498_y crossref_primary_10_1038_s41523_022_00501_2 crossref_primary_10_1158_2159_8290_CD_22_0837 crossref_primary_10_3892_mco_2023_2648 crossref_primary_10_1053_j_seminoncol_2020_07_008 crossref_primary_10_1016_j_annonc_2024_09_001 crossref_primary_10_1186_s12885_021_08894_2 crossref_primary_10_3892_mco_2023_2643 crossref_primary_10_1016_j_clon_2020_04_008 crossref_primary_10_1053_j_seminoncol_2020_07_005 crossref_primary_10_3390_cancers12102731 crossref_primary_10_3390_cancers15061738 crossref_primary_10_3390_ijms24043590 crossref_primary_10_1016_j_molstruc_2022_132524 crossref_primary_10_1007_s12282_023_01473_2 crossref_primary_10_3389_fphar_2022_924126 crossref_primary_10_1080_17425255_2023_2244870 crossref_primary_10_5306_wjco_v12_i3_164 crossref_primary_10_3390_jpm13091339 crossref_primary_10_1016_j_survophthal_2023_10_002 crossref_primary_10_1089_mab_2021_0048 crossref_primary_10_1186_s12967_021_03113_9 crossref_primary_10_1097_CCO_0000000000000682 crossref_primary_10_1177_17588359211059873 crossref_primary_10_1016_j_breast_2024_103830 crossref_primary_10_1016_j_clbc_2021_05_014 crossref_primary_10_1016_j_cpccr_2025_100392 crossref_primary_10_3389_fonc_2021_627223 crossref_primary_10_1016_j_cllc_2021_07_011 crossref_primary_10_3389_fonc_2022_919072 crossref_primary_10_1016_j_clgc_2025_102359 crossref_primary_10_3322_caac_21705 crossref_primary_10_1371_journal_pone_0241775 crossref_primary_10_1002_mco2_671 crossref_primary_10_1016_j_ejmech_2022_114304 crossref_primary_10_1016_j_ejmech_2025_117877 crossref_primary_10_1186_s40164_025_00632_9 crossref_primary_10_1016_j_biopha_2024_116522 crossref_primary_10_1007_s00761_020_00718_5 crossref_primary_10_1007_s10120_021_01164_x crossref_primary_10_3390_ijms242316823 crossref_primary_10_1016_j_dld_2023_09_015 crossref_primary_10_3390_nano13172476 crossref_primary_10_1038_s44276_024_00106_1 crossref_primary_10_4103_jcrt_jcrt_979_24 crossref_primary_10_1016_j_heliyon_2024_e30444 crossref_primary_10_3390_cancers13061331 crossref_primary_10_58931_cot_2025_2235 crossref_primary_10_1016_j_clbc_2023_09_005 crossref_primary_10_1007_s40259_024_00660_7 crossref_primary_10_1016_j_critrevonc_2020_102988 crossref_primary_10_1007_s12672_024_01192_w crossref_primary_10_1080_14796694_2025_2560678 crossref_primary_10_1186_s12885_021_08708_5 crossref_primary_10_1016_j_critrevonc_2024_104405 crossref_primary_10_1097_CAD_0000000000001191 crossref_primary_10_1016_j_ctarc_2025_100997 crossref_primary_10_1097_CCO_0000000000000656 crossref_primary_10_2147_OTT_S341290 crossref_primary_10_2147_BCTT_S245024 crossref_primary_10_2174_0109298673283289231214095230 crossref_primary_10_1016_j_annonc_2020_09_010 crossref_primary_10_4103_ijmpo_ijmpo_98_20 crossref_primary_10_1038_s41598_021_91588_3 crossref_primary_10_3389_fonc_2024_1339806 crossref_primary_10_15252_emmm_201911498 crossref_primary_10_1016_j_ctrv_2021_102225 crossref_primary_10_1097_COC_0000000000001126 crossref_primary_10_1177_1758835920986518 crossref_primary_10_4103_sjg_sjg_367_21 crossref_primary_10_3390_molecules30143026 crossref_primary_10_1080_2162402X_2020_1777625 crossref_primary_10_1056_NEJMoa2112431 crossref_primary_10_1016_j_bulcan_2025_05_008 crossref_primary_10_1007_s40135_024_00322_5 crossref_primary_10_1111_his_15346 crossref_primary_10_1038_s41523_021_00265_1 crossref_primary_10_3389_fonc_2021_672262 crossref_primary_10_3389_fphar_2025_1574286 crossref_primary_10_3390_ijms25158386 crossref_primary_10_1016_S1470_2045_20_30112_1 crossref_primary_10_1186_s13019_023_02181_w crossref_primary_10_3892_ol_2025_15154 crossref_primary_10_1016_j_clbc_2020_11_019 crossref_primary_10_1016_j_ejphar_2024_177076 crossref_primary_10_1038_s41571_021_00470_8 crossref_primary_10_1007_s12609_020_00356_1 crossref_primary_10_3389_fonc_2022_925551 crossref_primary_10_3390_molecules30071398 crossref_primary_10_1007_s11912_024_01593_8 crossref_primary_10_1038_s41419_024_06572_2 crossref_primary_10_2147_BCTT_S480796 crossref_primary_10_1007_s12282_024_01600_7 crossref_primary_10_3389_fonc_2024_1451230 crossref_primary_10_1007_s00432_023_05496_2 crossref_primary_10_1007_s12254_025_01068_x crossref_primary_10_3390_cancers16203517 crossref_primary_10_1007_s00129_021_04789_2 crossref_primary_10_1093_oncolo_oyac247 crossref_primary_10_1007_s10928_023_09884_6 crossref_primary_10_2174_1875318302010010038 crossref_primary_10_3389_fonc_2023_1100332 crossref_primary_10_1146_annurev_pathol_042420_093238 crossref_primary_10_1038_s41467_023_38032_4 crossref_primary_10_1016_j_clbc_2024_01_009 crossref_primary_10_1080_13543784_2021_1940950 crossref_primary_10_1007_s11864_020_00780_6 crossref_primary_10_3390_ph16101450 crossref_primary_10_1038_s41573_022_00579_0 crossref_primary_10_1097_CCO_0000000000001141 crossref_primary_10_1002_mco2_624 crossref_primary_10_1186_s11658_024_00555_z crossref_primary_10_3390_biomedicines10102511 crossref_primary_10_3390_cells14161282 crossref_primary_10_1016_j_ctrv_2022_102363 crossref_primary_10_1016_j_ebiom_2023_104571 crossref_primary_10_1007_s11912_023_01432_2 crossref_primary_10_1007_s11912_023_01478_2 crossref_primary_10_1186_s12967_025_06082_5 crossref_primary_10_1007_s12282_020_01153_5 crossref_primary_10_1200_EDBK_25_473384 crossref_primary_10_3389_fonc_2023_1097983 crossref_primary_10_20935_AcadOnco7882 crossref_primary_10_1007_s12032_023_02026_5 crossref_primary_10_1007_s13311_022_01261_4 crossref_primary_10_5858_arpa_2022_0335_RA crossref_primary_10_1016_j_hoc_2021_02_008 crossref_primary_10_1038_s41698_025_00801_3 crossref_primary_10_2217_fon_2022_0407 crossref_primary_10_1002_cam4_7168 crossref_primary_10_3389_fonc_2024_1484750 crossref_primary_10_1159_000522068 crossref_primary_10_1007_s00428_023_03640_4 crossref_primary_10_3390_pharmaceutics13050723 crossref_primary_10_1186_s43556_025_00261_y crossref_primary_10_1002_cpt_2096 crossref_primary_10_1016_j_addr_2020_12_002 crossref_primary_10_1016_j_bcp_2022_115049 crossref_primary_10_1016_S1470_2045_24_00159_1 crossref_primary_10_1007_s00129_022_04934_5 crossref_primary_10_1016_S1470_2045_21_00086_3 crossref_primary_10_2147_CMAR_S235121 crossref_primary_10_3390_cancers12030670 crossref_primary_10_1038_s41416_024_02766_9 crossref_primary_10_1097_GCO_0000000000000677 crossref_primary_10_1515_biol_2025_1113 crossref_primary_10_1038_s41568_020_00322_0 crossref_primary_10_1016_j_ejca_2021_06_033 crossref_primary_10_2147_JIR_S368138 crossref_primary_10_1016_j_yao_2024_01_008 crossref_primary_10_1002_jev2_12070 crossref_primary_10_3390_pharmaceutics15071848 crossref_primary_10_1016_j_esmoop_2024_102995 crossref_primary_10_1002_ardp_202400969 crossref_primary_10_1007_s12272_022_01402_5 crossref_primary_10_1186_s43556_022_00100_4 crossref_primary_10_1007_s11864_021_00879_4 crossref_primary_10_1016_j_bpobgyn_2022_02_004 crossref_primary_10_1038_s41467_023_42689_2 crossref_primary_10_1016_j_ejps_2025_107234 crossref_primary_10_1172_JCI172156 crossref_primary_10_1080_14712598_2020_1752176 crossref_primary_10_1177_1758835920962997 crossref_primary_10_1016_j_annonc_2022_08_001 crossref_primary_10_1097_MD_0000000000032882 crossref_primary_10_1002_cam4_3824 crossref_primary_10_1038_s41598_024_61957_9 crossref_primary_10_1002_jcph_2297 crossref_primary_10_1038_s41417_023_00701_3 crossref_primary_10_1055_a_1397_7170 crossref_primary_10_1080_14712598_2021_1890710 crossref_primary_10_1002_jcph_2295 crossref_primary_10_1016_j_micromeso_2021_110967 crossref_primary_10_1097_PGP_0000000000001059 crossref_primary_10_1016_j_bioorg_2024_107697 crossref_primary_10_1038_s41401_025_01647_y crossref_primary_10_3390_cancers16234036 crossref_primary_10_26442_18151434_2025_2_203315 crossref_primary_10_1038_s41698_022_00338_9 crossref_primary_10_1056_NEJMcpc2309499 crossref_primary_10_1016_j_phrs_2025_107687 crossref_primary_10_1016_j_heliyon_2023_e15164 crossref_primary_10_1007_s11912_023_01469_3 crossref_primary_10_1016_j_ccell_2020_03_007 crossref_primary_10_1007_s40801_022_00340_4 crossref_primary_10_3390_cancers17101654 crossref_primary_10_7759_cureus_79734 crossref_primary_10_2217_fon_2022_0214 crossref_primary_10_3390_jcm11195891 crossref_primary_10_1093_abt_tbac020 crossref_primary_10_1200_JCO_23_01909 crossref_primary_10_3389_fphar_2022_977660 crossref_primary_10_3390_ijms23126547 crossref_primary_10_4103_ijmpo_ijmpo_252_19 crossref_primary_10_1093_abt_tbac024 crossref_primary_10_1055_s_0042_1755569 crossref_primary_10_1016_j_ctrv_2021_102286 crossref_primary_10_1055_a_2515_2366 crossref_primary_10_3389_fonc_2022_889017 crossref_primary_10_1080_14740338_2021_1983541 crossref_primary_10_3389_fphar_2024_1362484 crossref_primary_10_1007_s11060_025_05188_6 crossref_primary_10_1097_CAD_0000000000001117 crossref_primary_10_1007_s10549_024_07321_x crossref_primary_10_1200_EDBK_100023 crossref_primary_10_1080_14737140_2020_1807947 crossref_primary_10_1136_bcr_2021_243881 crossref_primary_10_1080_14712598_2023_2277915 crossref_primary_10_1111_his_14877 crossref_primary_10_3389_fimmu_2022_799988 crossref_primary_10_1159_000516420 crossref_primary_10_3390_molecules26195847 crossref_primary_10_1007_s00508_023_02254_9 crossref_primary_10_1158_2159_8290_CD_20_1434 crossref_primary_10_1002_adtp_202400018 crossref_primary_10_1136_bmjopen_2023_077108 crossref_primary_10_1177_10732748221099230 crossref_primary_10_1186_s12967_024_05133_7 crossref_primary_10_1080_14737167_2021_1848553 crossref_primary_10_3390_cancers12020400 crossref_primary_10_3390_cancers16132367 crossref_primary_10_1016_j_bbcan_2022_188789 crossref_primary_10_3390_cancers14194828 crossref_primary_10_1096_fj_202101441R crossref_primary_10_1158_1078_0432_CCR_23_0633 crossref_primary_10_25259_IJRSMS_40_2025 crossref_primary_10_1007_s11523_022_00923_9 crossref_primary_10_1080_10543406_2024_2387364 crossref_primary_10_1002_cam4_6041 crossref_primary_10_1177_17588359231225029 crossref_primary_10_3390_ijms26136523 crossref_primary_10_1093_abt_tbac001 crossref_primary_10_1038_s41573_021_00195_4 crossref_primary_10_3390_ijms25063354 crossref_primary_10_3390_ijms24098206 crossref_primary_10_1016_j_ctrv_2022_102384 crossref_primary_10_1016_j_ctrv_2022_102378 crossref_primary_10_3390_cancers12082081 crossref_primary_10_1158_1078_0432_CCR_23_0640 crossref_primary_10_3390_cancers16234082 crossref_primary_10_1002_mco2_70162 crossref_primary_10_1016_j_biopha_2020_110407 crossref_primary_10_1038_s41571_024_00874_2 crossref_primary_10_1038_s41598_021_96521_2 crossref_primary_10_1371_journal_pone_0246197 crossref_primary_10_3390_immuno3020013 crossref_primary_10_1159_000512283 crossref_primary_10_1038_s41467_024_46811_w crossref_primary_10_3389_fphar_2023_1244597 crossref_primary_10_1016_j_ctrv_2023_102672 crossref_primary_10_1080_0284186X_2023_2176257 crossref_primary_10_3390_cancers14112795 crossref_primary_10_1038_s41392_023_01322_w crossref_primary_10_1016_j_tranon_2025_102284 crossref_primary_10_1080_24745332_2022_2108936 crossref_primary_10_3389_fonc_2021_731210 crossref_primary_10_1016_j_rmclc_2025_05_003 crossref_primary_10_1038_s41523_024_00669_9 crossref_primary_10_1016_j_ctrv_2023_102670 crossref_primary_10_3390_jpm14070719 crossref_primary_10_1093_abt_tbab017 crossref_primary_10_3390_jpm11080808 crossref_primary_10_3390_ph18060848 crossref_primary_10_1186_s12885_020_07546_1 crossref_primary_10_1016_j_ejpb_2021_10_016 crossref_primary_10_1097_MD_0000000000038911 crossref_primary_10_1186_s40959_023_00163_4 crossref_primary_10_1186_s40001_022_00894_7 crossref_primary_10_1007_s12032_022_01812_x crossref_primary_10_3390_cancers14092136 crossref_primary_10_3390_cancers12061573 crossref_primary_10_1089_mab_2023_0033 crossref_primary_10_3390_cancers14010044 crossref_primary_10_1016_j_breast_2021_11_016 crossref_primary_10_1016_j_critrevonc_2024_104274 crossref_primary_10_1186_s13058_020_1252_7 crossref_primary_10_1007_s40487_023_00241_8 crossref_primary_10_1158_1078_0432_CCR_24_1513 crossref_primary_10_3390_ijms26031079 crossref_primary_10_1007_s11864_023_01137_5 crossref_primary_10_1016_S1470_2045_24_00128_1 crossref_primary_10_1080_14712598_2021_1846714 crossref_primary_10_1186_s13046_023_02918_4 crossref_primary_10_1002_cncr_33102 crossref_primary_10_1080_14712598_2020_1789096 crossref_primary_10_3389_fonc_2024_1447508 crossref_primary_10_1177_17588359251318853 crossref_primary_10_1016_j_jaccao_2022_09_007 crossref_primary_10_1080_14737140_2023_2218090 crossref_primary_10_3390_biomedicines11123164 crossref_primary_10_3390_pharmaceutics12090802 crossref_primary_10_3390_cancers14205136 crossref_primary_10_1038_s41598_025_02550_6 crossref_primary_10_1051_e3sconf_202455305031 crossref_primary_10_3390_ph16060794 crossref_primary_10_1002_cam4_5021 crossref_primary_10_3390_diseases10020023 crossref_primary_10_1007_s11912_021_01080_4 crossref_primary_10_1177_17588359221106564 crossref_primary_10_1007_s15015_023_3073_x crossref_primary_10_3390_cancers13112660 crossref_primary_10_1007_s40263_021_00894_x crossref_primary_10_1007_s40264_023_01328_x crossref_primary_10_1200_JCO_23_02010 crossref_primary_10_1159_000506098 crossref_primary_10_1093_carcin_bgae082 crossref_primary_10_1158_2159_8290_CD_23_0091 crossref_primary_10_1186_s12885_024_11851_4 crossref_primary_10_1080_17425255_2022_2162383 crossref_primary_10_1016_j_ejso_2023_03_226 crossref_primary_10_1016_j_omto_2021_08_005 crossref_primary_10_3390_cancers13236012 crossref_primary_10_1186_s13058_022_01551_x crossref_primary_10_3390_genes13112065 crossref_primary_10_1080_1120009X_2021_2009722 crossref_primary_10_3390_ijms252313090 crossref_primary_10_1016_j_eclinm_2025_103088 crossref_primary_10_1016_j_heliyon_2023_e23367 crossref_primary_10_1111_cas_15474 crossref_primary_10_3390_biomedicines12071491 crossref_primary_10_1007_s10147_023_02422_x crossref_primary_10_1016_j_pacs_2025_100764 crossref_primary_10_3390_jcm12216708 crossref_primary_10_1016_j_mpsur_2023_12_015 crossref_primary_10_1016_j_critrevonc_2025_104787 crossref_primary_10_1016_j_gofs_2025_03_003 crossref_primary_10_1159_000545018 crossref_primary_10_3389_fonc_2023_1268260 crossref_primary_10_1007_s15013_022_4374_4 crossref_primary_10_1007_s40265_020_01281_4 crossref_primary_10_3390_biomedicines12030500 crossref_primary_10_3389_fonc_2024_1276637 crossref_primary_10_1080_14656566_2024_2402022 crossref_primary_10_1007_s12032_022_01749_1 crossref_primary_10_1016_j_compbiomed_2023_107080 crossref_primary_10_1007_s00428_025_04139_w crossref_primary_10_1038_s43018_022_00386_x crossref_primary_10_1007_s00280_021_04254_w crossref_primary_10_3390_cancers14205115 crossref_primary_10_1002_nano_202300191 crossref_primary_10_1016_j_biopha_2024_117363 crossref_primary_10_1515_med_2023_0725 crossref_primary_10_1016_j_bmcl_2022_128876 crossref_primary_10_1053_j_seminoncol_2021_06_003 crossref_primary_10_1016_j_critrevonc_2024_104265 crossref_primary_10_1158_2159_8290_CD_22_1368 crossref_primary_10_1016_j_breast_2025_104421 crossref_primary_10_1097_GCO_0000000000000838 crossref_primary_10_1007_s00292_022_01139_4 crossref_primary_10_1177_17588359231220501 crossref_primary_10_3390_pharmaceutics14071338 crossref_primary_10_1080_21645515_2021_1999711 crossref_primary_10_1186_s10020_023_00736_0 crossref_primary_10_1038_s41467_023_44140_y crossref_primary_10_1016_j_breast_2025_104428 crossref_primary_10_1097_MD_0000000000024995 crossref_primary_10_1159_000547685 crossref_primary_10_1007_s12254_021_00763_9 crossref_primary_10_1016_S0140_6736_23_00805_X crossref_primary_10_3389_fimmu_2023_1203073 crossref_primary_10_3389_fonc_2024_1470560 crossref_primary_10_1002_cpt_2278 crossref_primary_10_1016_j_breast_2021_10_009 crossref_primary_10_1056_NEJMc2205309 crossref_primary_10_1016_j_clbc_2022_02_002 crossref_primary_10_1016_j_tranon_2024_102100 crossref_primary_10_1158_1078_0432_CCR_24_1552 crossref_primary_10_1002_psp4_70013 crossref_primary_10_1016_S0007_4551_21_00631_7 crossref_primary_10_1007_s11523_025_01140_w crossref_primary_10_2147_DDDT_S508773 crossref_primary_10_3390_cells10030659 crossref_primary_10_3390_biom13010093 crossref_primary_10_1002_cam4_5693 crossref_primary_10_1056_NEJMe1916310 crossref_primary_10_1080_13543784_2020_1792443 crossref_primary_10_3390_cancers16040800 crossref_primary_10_1080_14737167_2023_2291157 crossref_primary_10_3389_fphar_2023_1332539 crossref_primary_10_1016_j_annonc_2024_08_2347 crossref_primary_10_1080_19420862_2023_2229101 crossref_primary_10_1200_EDBK_351222 crossref_primary_10_1007_s10549_023_07171_z crossref_primary_10_1186_s12885_024_12818_1 crossref_primary_10_3390_cancers12103021 crossref_primary_10_3390_cancers13225771 crossref_primary_10_1016_j_ijwd_2021_10_006 crossref_primary_10_1055_a_2375_5194 crossref_primary_10_1158_0008_5472_CAN_22_0787 crossref_primary_10_3390_cancers14040965 crossref_primary_10_1007_s13193_024_01936_8 crossref_primary_10_1007_s00259_024_06929_x crossref_primary_10_1016_j_ejca_2023_113379 crossref_primary_10_3390_cancers13122898 crossref_primary_10_1002_cpt_2291 crossref_primary_10_1053_j_semnuclmed_2022_03_004 crossref_primary_10_3390_cancers12030636 crossref_primary_10_1007_s00428_024_03856_y crossref_primary_10_1158_1078_0432_CCR_21_0397 crossref_primary_10_1177_17588359231183679 crossref_primary_10_1016_j_isci_2024_111536 crossref_primary_10_1055_s_0041_1731861 crossref_primary_10_3390_jcm9061984 crossref_primary_10_1055_a_2300_5326 crossref_primary_10_1186_s13058_025_02088_5 crossref_primary_10_3390_cancers16020335 crossref_primary_10_3233_BD_210032 crossref_primary_10_1186_s40164_022_00363_1 crossref_primary_10_1038_s41587_025_02772_z crossref_primary_10_2217_cns_2022_0018 crossref_primary_10_3389_fonc_2025_1459444 crossref_primary_10_1007_s11307_020_01571_z crossref_primary_10_1016_j_ymthe_2020_12_037 crossref_primary_10_1016_j_critrevonc_2024_104292 crossref_primary_10_1002_cam4_4381 crossref_primary_10_1007_s40265_022_01736_w crossref_primary_10_1016_j_toxrep_2025_102054 crossref_primary_10_1038_s41571_025_01064_4 crossref_primary_10_1111_iju_14925 crossref_primary_10_1038_s41577_025_01207_9 crossref_primary_10_1080_21645515_2025_2472493 crossref_primary_10_1158_1535_7163_MCT_24_0763 crossref_primary_10_1177_10781552221119797 crossref_primary_10_1158_2159_8290_CD_24_0306 crossref_primary_10_1159_000512328 crossref_primary_10_1007_s12032_024_02504_4 crossref_primary_10_1016_j_ejca_2022_04_039 crossref_primary_10_3390_genes13060960 crossref_primary_10_1158_1078_0432_CCR_20_2701 crossref_primary_10_1200_GO_22_00354 crossref_primary_10_1097_GCO_0000000000000642 crossref_primary_10_3390_cancers12113271 crossref_primary_10_1007_s40265_020_01272_5 crossref_primary_10_1177_10781552241228827 crossref_primary_10_1038_s41392_021_00868_x crossref_primary_10_1016_j_clbc_2022_03_002 crossref_primary_10_3389_fcvm_2023_1002438 crossref_primary_10_1002_cmdc_202200032 crossref_primary_10_1093_jnci_djac227 crossref_primary_10_3390_ijms242216056 crossref_primary_10_1200_EDBK_280775 crossref_primary_10_1136_jitc_2022_004841 crossref_primary_10_1038_s41571_021_00565_2 crossref_primary_10_1097_MD_0000000000025685 crossref_primary_10_2147_BCTT_S268451 crossref_primary_10_3389_fonc_2025_1582498 crossref_primary_10_1186_s13045_022_01362_9 crossref_primary_10_1016_S0007_4551_21_00633_0 crossref_primary_10_1007_s00259_020_05094_1 crossref_primary_10_1038_s41523_023_00522_5 crossref_primary_10_1080_14737140_2023_2171993 crossref_primary_10_32604_Oncologie_2021_016277 crossref_primary_10_1007_s00292_022_01124_x crossref_primary_10_1016_j_jaccao_2025_05_006 crossref_primary_10_1177_17588359231187201 crossref_primary_10_3390_cancers15041278 crossref_primary_10_1016_j_drup_2025_101288 crossref_primary_10_1089_mab_2022_0023 crossref_primary_10_1080_14796694_2024_2407756 crossref_primary_10_1007_s12282_020_01192_y crossref_primary_10_1016_j_canlet_2025_217900 crossref_primary_10_1080_14737140_2021_1894932 crossref_primary_10_1016_j_pathol_2023_03_007 crossref_primary_10_1016_j_jconrel_2020_10_031 crossref_primary_10_1002_jcsm_13691 crossref_primary_10_1007_s11864_023_01072_5 crossref_primary_10_1007_s00761_022_01105_y crossref_primary_10_1186_s12885_024_12749_x crossref_primary_10_1186_s40164_022_00347_1 crossref_primary_10_1007_s12094_020_02333_7 crossref_primary_10_1080_07853890_2024_2434182 crossref_primary_10_1073_pnas_2209563119 crossref_primary_10_1038_s41467_024_48798_w crossref_primary_10_1016_j_annonc_2025_02_011 crossref_primary_10_1097_GRF_0000000000000721 crossref_primary_10_1016_j_mam_2022_101150 crossref_primary_10_1038_s41388_022_02443_2 crossref_primary_10_1007_s11654_024_00598_w crossref_primary_10_1177_17588359231175440 crossref_primary_10_1016_j_mri_2022_11_009 crossref_primary_10_5306_wjco_v12_i10_868 crossref_primary_10_1016_j_clbc_2024_05_001 crossref_primary_10_3390_cancers15112908 crossref_primary_10_1016_j_cpt_2023_10_004 crossref_primary_10_1021_acs_jmedchem_5c00466 crossref_primary_10_1200_EDBK_433694 crossref_primary_10_3390_cancers15153886 crossref_primary_10_1038_s43018_022_00491_x crossref_primary_10_1002_cncr_35349 crossref_primary_10_1177_17588359211059587 crossref_primary_10_1007_s10549_022_06731_z crossref_primary_10_1007_s12325_022_02273_4 crossref_primary_10_1080_10717544_2022_2069883 crossref_primary_10_1016_j_cell_2023_01_040 crossref_primary_10_1159_000510998 crossref_primary_10_1007_s10549_022_06775_1 crossref_primary_10_1016_j_critrevonc_2025_104707 crossref_primary_10_3892_or_2025_8901 crossref_primary_10_1016_j_ejmech_2024_116899 crossref_primary_10_1007_s10549_021_06313_5 crossref_primary_10_1007_s12672_025_02495_2 crossref_primary_10_1016_j_esmorw_2024_100095 crossref_primary_10_1371_journal_pone_0292871 crossref_primary_10_3389_fonc_2023_1210873 crossref_primary_10_1038_s41392_024_01779_3 crossref_primary_10_1080_14712598_2020_1757067 crossref_primary_10_1186_s12885_021_08504_1 crossref_primary_10_3390_ph14070674 crossref_primary_10_1158_1078_0432_CCR_22_3861 crossref_primary_10_3390_ijms231911687 crossref_primary_10_1093_oncolo_oyaf174 crossref_primary_10_1007_s12282_020_01137_5 crossref_primary_10_1016_j_apsb_2024_12_036 crossref_primary_10_1158_1078_0432_CCR_21_3247 crossref_primary_10_1007_s11864_023_01108_w crossref_primary_10_1016_j_pharmthera_2021_108106 crossref_primary_10_1007_s11864_025_01336_2 crossref_primary_10_1016_j_clbc_2022_02_008 crossref_primary_10_1016_j_nucmedbio_2024_108880 crossref_primary_10_1038_s41571_023_00849_9 crossref_primary_10_1007_s11864_024_01183_7 crossref_primary_10_1177_00033197251356583 crossref_primary_10_2147_BCTT_S341857 crossref_primary_10_1016_j_breast_2023_103669 crossref_primary_10_1186_s13058_023_01664_x crossref_primary_10_2147_DDDT_S281599 crossref_primary_10_1002_hed_27395 crossref_primary_10_1177_17588359251324889 crossref_primary_10_3390_cancers15010051 crossref_primary_10_1158_1078_0432_CCR_22_2981 crossref_primary_10_1056_NEJMoa2004413 crossref_primary_10_1155_2021_5575286 crossref_primary_10_1186_s12967_024_05568_y crossref_primary_10_1007_s40265_020_01411_y crossref_primary_10_3390_ph18060895 crossref_primary_10_1016_S0140_6736_23_00725_0 crossref_primary_10_1136_jitc_2021_002597 crossref_primary_10_1159_000533866 crossref_primary_10_1007_s40487_024_00280_9 crossref_primary_10_47102_annals_acadmedsg_2025229 crossref_primary_10_1038_s41467_022_35245_x crossref_primary_10_1016_j_acra_2022_12_008 crossref_primary_10_1016_j_critrevonc_2023_104189 crossref_primary_10_1158_2159_8290_CD_19_1014 crossref_primary_10_1016_j_biopha_2024_117106 crossref_primary_10_1007_s00595_022_02524_5 crossref_primary_10_1016_j_critrevonc_2023_104185 crossref_primary_10_3390_cancers15071987 crossref_primary_10_1038_s41374_022_00804_9 crossref_primary_10_1093_oncolo_oyaf152 crossref_primary_10_1186_s13045_021_01035_z crossref_primary_10_3390_molecules25122861 crossref_primary_10_1186_s12951_023_01857_8 crossref_primary_10_1186_s13058_025_01967_1 crossref_primary_10_1016_j_esmorw_2024_100043 crossref_primary_10_1016_j_ejmech_2020_112364 crossref_primary_10_1016_S0140_6736_20_32381_3 crossref_primary_10_3390_cancers14040911 crossref_primary_10_1007_s10549_021_06217_4 crossref_primary_10_1007_s12282_025_01675_w crossref_primary_10_1038_s41467_024_50056_y crossref_primary_10_1186_s12967_024_05985_z crossref_primary_10_1186_s13046_024_03143_3 crossref_primary_10_1055_a_2510_1821 crossref_primary_10_2147_BCTT_S489419 crossref_primary_10_3322_caac_21634 crossref_primary_10_3390_cancers16162894 crossref_primary_10_3390_ijms222312809 crossref_primary_10_1007_s10549_020_05891_0 crossref_primary_10_1007_s11912_021_01038_6 crossref_primary_10_1016_j_clbc_2024_04_001 crossref_primary_10_1038_s41698_025_00885_x crossref_primary_10_1016_j_canlet_2021_04_023 crossref_primary_10_1016_j_clbc_2024_04_003 crossref_primary_10_1007_s11060_024_04681_8 crossref_primary_10_1007_s11912_021_01114_x crossref_primary_10_1080_17425255_2024_2302460 crossref_primary_10_1039_D2BM01769E crossref_primary_10_1186_s13045_022_01397_y crossref_primary_10_3389_fphar_2024_1390361 crossref_primary_10_1002_cnr2_1841 crossref_primary_10_1093_oncolo_oyae280 crossref_primary_10_1177_17534666241299935 crossref_primary_10_1016_j_annonc_2023_04_516 crossref_primary_10_1016_j_esmoop_2025_105330 crossref_primary_10_3389_fonc_2023_1066007 crossref_primary_10_1186_s12967_024_05546_4 crossref_primary_10_3390_cancers12092630 crossref_primary_10_1007_s10549_021_06306_4 crossref_primary_10_3390_cancers15061845 crossref_primary_10_1016_j_jpba_2025_116843 crossref_primary_10_1097_PPO_0000000000000629 crossref_primary_10_3390_jpm11060518 crossref_primary_10_1093_oncolo_oyae144 crossref_primary_10_3390_cancers14030579 crossref_primary_10_1097_PPO_0000000000000627 crossref_primary_10_1093_neuonc_noae163 crossref_primary_10_1016_S0140_6736_23_00679_7 crossref_primary_10_1080_14796694_2025_2535171 crossref_primary_10_1097_PPO_0000000000000630 crossref_primary_10_1016_j_breast_2023_03_007 crossref_primary_10_1038_s41571_019_0325_y crossref_primary_10_1038_s41698_024_00788_3 crossref_primary_10_3389_fonc_2024_1323366 crossref_primary_10_1038_s41467_022_31601_z crossref_primary_10_1093_oncolo_oyaf229 crossref_primary_10_1155_2023_6621409 crossref_primary_10_1136_jcp_2023_209055 crossref_primary_10_1186_s13058_023_01717_1 crossref_primary_10_1016_j_actaastro_2021_09_045 crossref_primary_10_1016_j_urolonc_2023_06_006 crossref_primary_10_1186_s13244_024_01771_z crossref_primary_10_1038_s41416_023_02272_4 crossref_primary_10_1007_s10238_025_01655_6 crossref_primary_10_2217_fon_2021_0192 crossref_primary_10_7759_cureus_59652 crossref_primary_10_1016_j_jconrel_2021_10_006 crossref_primary_10_3390_cancers15153837 crossref_primary_10_3389_fonc_2023_1091249 crossref_primary_10_1021_acscentsci_1c01024 crossref_primary_10_1016_j_esmorc_2025_100041 crossref_primary_10_3390_pharmaceutics14081707 crossref_primary_10_1177_17588359241279695 crossref_primary_10_1186_s12935_025_03680_7 crossref_primary_10_2217_fon_2020_0224 crossref_primary_10_1007_s00129_024_05216_y crossref_primary_10_3390_jcm13226739 crossref_primary_10_1007_s11523_023_01030_z crossref_primary_10_1002_cai2_8 crossref_primary_10_1016_j_clbc_2022_07_005 crossref_primary_10_1007_s12254_021_00781_7 crossref_primary_10_1097_MD_0000000000029304 crossref_primary_10_2217_fon_2020_0219 crossref_primary_10_3389_fonc_2022_817070 crossref_primary_10_1016_j_canlet_2022_216024 crossref_primary_10_3389_fonc_2021_718590 crossref_primary_10_1007_s10120_021_01165_w crossref_primary_10_3390_cancers15153801 crossref_primary_10_1080_14740338_2025_2449991 crossref_primary_10_1124_jpet_123_002048 crossref_primary_10_1080_14737140_2022_2147510 crossref_primary_10_1007_s12609_023_00486_2 crossref_primary_10_1093_oncolo_oyad023 crossref_primary_10_1007_s12254_022_00810_z crossref_primary_10_1097_PPO_0000000000000633 crossref_primary_10_1097_PPO_0000000000000634 crossref_primary_10_1016_j_apsb_2022_09_021 crossref_primary_10_1016_j_clbc_2025_05_015 crossref_primary_10_1055_a_1270_7481 crossref_primary_10_3390_ijms24054590 crossref_primary_10_1200_GO_24_00132 crossref_primary_10_1016_j_bulcan_2020_11_007 crossref_primary_10_3390_ijms21176018 crossref_primary_10_1007_s10555_024_10231_5 crossref_primary_10_1186_s12916_022_02346_9 crossref_primary_10_1007_s10549_021_06150_6 crossref_primary_10_1080_17512433_2022_2121705 crossref_primary_10_1038_s41523_022_00404_2 crossref_primary_10_1007_s10549_022_06575_7 crossref_primary_10_1186_s12935_021_02182_6 crossref_primary_10_1016_j_jaad_2024_08_036 crossref_primary_10_3390_cancers14143337 crossref_primary_10_1093_omcr_omad135 crossref_primary_10_1186_s12905_025_03828_7 crossref_primary_10_7759_cureus_55483 crossref_primary_10_1158_1541_7786_MCR_21_0545 crossref_primary_10_1038_s41523_021_00220_0 crossref_primary_10_1177_17588359211013326 crossref_primary_10_1016_j_ijbiomac_2021_03_075 crossref_primary_10_3390_cancers14041022 crossref_primary_10_1016_j_ctrv_2022_102434 crossref_primary_10_1158_1078_0432_CCR_23_0103 crossref_primary_10_1016_j_clbc_2025_04_007 crossref_primary_10_1208_s12248_025_01087_w crossref_primary_10_1016_j_critrevonc_2024_104527 crossref_primary_10_3390_cancers12071902 crossref_primary_10_1016_j_ctrv_2022_102436 crossref_primary_10_1038_s41467_024_51498_0 crossref_primary_10_1097_CCO_0000000000000779 crossref_primary_10_1002_cac2_12358 crossref_primary_10_3390_biomedicines9111687 crossref_primary_10_3390_ijms241511903 crossref_primary_10_3390_cancers15020362 crossref_primary_10_2147_BCTT_S270799 crossref_primary_10_3389_fonc_2023_1229222 crossref_primary_10_1016_j_ctrv_2020_102033 crossref_primary_10_1002_cmdc_202400109 crossref_primary_10_3390_molecules27196632 crossref_primary_10_1016_j_bulcan_2024_04_004 crossref_primary_10_1016_j_annonc_2021_06_023 crossref_primary_10_1055_a_1471_4063 crossref_primary_10_1097_CCO_0000000000000988 crossref_primary_10_1158_1078_0432_CCR_23_1209 crossref_primary_10_1080_13543784_2022_2159805 crossref_primary_10_1016_j_critrevonc_2023_104212 crossref_primary_10_2147_OTT_S335934 crossref_primary_10_3390_cancers13164008 crossref_primary_10_1097_CCO_0000000000000984 crossref_primary_10_1002_adbi_202101065 crossref_primary_10_1016_j_annonc_2020_10_001 crossref_primary_10_3390_cancers16010087 crossref_primary_10_1080_14737140_2021_1996229 crossref_primary_10_2147_BCTT_S448191 crossref_primary_10_1007_s12254_021_00792_4 crossref_primary_10_1186_s13046_021_02098_z crossref_primary_10_3390_antib10030030 crossref_primary_10_3390_biomedicines12050953 crossref_primary_10_1016_j_hoc_2022_08_012 crossref_primary_10_2147_BCTT_S385341 crossref_primary_10_1016_j_ctrv_2020_102064 crossref_primary_10_57264_cer_2023_0153 crossref_primary_10_1038_s41523_023_00584_5 crossref_primary_10_1186_s13073_025_01427_7 crossref_primary_10_1016_j_preme_2025_100041 crossref_primary_10_1007_s40266_021_00889_9 crossref_primary_10_1016_j_phrs_2024_107431 crossref_primary_10_1016_j_ctrv_2022_102417 crossref_primary_10_1007_s12032_022_01805_w crossref_primary_10_1186_s12943_024_01963_7 crossref_primary_10_3389_fonc_2021_654974 crossref_primary_10_1016_j_lungcan_2023_03_003 crossref_primary_10_3389_fcell_2025_1451471 crossref_primary_10_1002_cncr_33906 crossref_primary_10_1158_1078_0432_CCR_20_3119 crossref_primary_10_1186_s13058_024_01823_8 crossref_primary_10_1002_cac2_12577 crossref_primary_10_7759_cureus_45474 crossref_primary_10_4103_1673_5374_308075 crossref_primary_10_1097_MJT_0000000000001894 crossref_primary_10_1002_cmdc_202000889 crossref_primary_10_1016_j_xcrm_2025_102213 crossref_primary_10_1001_jamanetworkopen_2025_27403 crossref_primary_10_1016_j_ejrad_2021_109948 crossref_primary_10_1016_j_breast_2023_01_005 crossref_primary_10_3389_fphar_2023_1274088 crossref_primary_10_1038_s41392_022_00947_7 crossref_primary_10_1200_GO_22_00126 crossref_primary_10_1080_14796694_2025_2470604 crossref_primary_10_3389_fphar_2022_921385 crossref_primary_10_1038_s41571_023_00756_z crossref_primary_10_3390_cancers13215257 crossref_primary_10_3390_ijms22020779 crossref_primary_10_1080_14796694_2025_2479417 crossref_primary_10_3390_cancers14133167 crossref_primary_10_1007_s10928_023_09850_2 crossref_primary_10_1002_adma_202300377 crossref_primary_10_3390_cancers17071203 crossref_primary_10_1016_j_cpet_2023_12_002 crossref_primary_10_1016_j_bulcan_2021_04_015 crossref_primary_10_1039_D5MD00141B crossref_primary_10_1093_eurheartj_ehae637 crossref_primary_10_1007_s11912_024_01628_0 crossref_primary_10_3390_reports8030126 crossref_primary_10_1038_s41591_022_01935_8 crossref_primary_10_1016_j_breast_2022_07_011 crossref_primary_10_1002_advs_202307865 crossref_primary_10_1016_j_lungcan_2021_11_016 crossref_primary_10_1016_j_microc_2025_114617 crossref_primary_10_1007_s10147_023_02414_x crossref_primary_10_1093_neuonc_noac144 crossref_primary_10_1111_eci_70001 crossref_primary_10_1111_ajco_13655 crossref_primary_10_7759_cureus_34724 crossref_primary_10_3390_cancers15030713 crossref_primary_10_1002_slct_202202259 crossref_primary_10_1007_s12672_024_01663_0 crossref_primary_10_1007_s40261_024_01400_z crossref_primary_10_1159_000511049 crossref_primary_10_1080_17460441_2022_2050692 crossref_primary_10_1186_s11671_025_04303_w crossref_primary_10_1080_14712598_2021_1840547 crossref_primary_10_1016_j_critrevonc_2023_103962 crossref_primary_10_1016_j_critrevonc_2023_103960 crossref_primary_10_1186_s13045_020_00881_7 crossref_primary_10_1016_j_biopha_2022_114047 crossref_primary_10_1080_14712598_2021_1912007 crossref_primary_10_1093_oncolo_oyac107 crossref_primary_10_3390_genes11101187 crossref_primary_10_1016_j_clbc_2024_08_010 crossref_primary_10_1093_eurheartj_ehac244 crossref_primary_10_1007_s40263_022_00975_5 crossref_primary_10_1016_j_bbcan_2021_188595 crossref_primary_10_1016_j_preteyeres_2024_101302 crossref_primary_10_1016_j_phrs_2023_106934 crossref_primary_10_1158_1078_0432_CCR_21_2600 crossref_primary_10_3390_cancers15082365 crossref_primary_10_1177_17588359241292266 crossref_primary_10_1016_j_anndiagpath_2022_151953 crossref_primary_10_1007_s12032_022_01849_y crossref_primary_10_1158_1078_0432_CCR_25_0634 crossref_primary_10_1038_s41591_025_03600_2 crossref_primary_10_1109_JBHI_2024_3429188 crossref_primary_10_1177_17588359211066677 crossref_primary_10_2174_0115748928267931231120065335 crossref_primary_10_7861_clinmed_2022_0514 crossref_primary_10_1093_jjco_hyae054 crossref_primary_10_1016_j_molimm_2022_10_005 crossref_primary_10_1016_j_cclet_2025_110960 crossref_primary_10_1055_a_2666_7519 crossref_primary_10_3390_antib12040072 crossref_primary_10_1016_j_bioorg_2025_108725 crossref_primary_10_1007_s12272_023_01433_6 crossref_primary_10_1007_s10549_024_07586_2 crossref_primary_10_2217_fon_2020_0046 crossref_primary_10_1016_j_ctrv_2021_102169 crossref_primary_10_1016_j_ctrv_2024_102847 crossref_primary_10_1080_14712598_2020_1776255 crossref_primary_10_1136_bmjopen_2022_070304 crossref_primary_10_1007_s00508_021_01987_9 crossref_primary_10_3389_fphar_2022_1067557 crossref_primary_10_3390_cancers16132466 crossref_primary_10_1111_cts_70313 crossref_primary_10_1055_s_0040_1720949 crossref_primary_10_1007_s10549_020_05754_8 crossref_primary_10_1016_j_annonc_2021_09_019 crossref_primary_10_1016_j_jjcc_2022_04_006 crossref_primary_10_1038_s41523_020_0153_3 crossref_primary_10_1039_D5CB00096C crossref_primary_10_3390_antib10010006 crossref_primary_10_1002_cnr2_1274 crossref_primary_10_1007_s12094_022_02803_0 crossref_primary_10_1093_neuonc_noac180 crossref_primary_10_3390_cancers13051015 crossref_primary_10_1002_cam4_5056 crossref_primary_10_3390_cancers14030778 crossref_primary_10_3389_fonc_2022_1039882 crossref_primary_10_1016_j_clbc_2025_02_016 crossref_primary_10_2217_fon_2020_0036 crossref_primary_10_1016_j_lungcan_2021_12_002 crossref_primary_10_3390_cancers15112872 crossref_primary_10_3390_ijms26020554 crossref_primary_10_1002_cac2_12517 crossref_primary_10_1080_14737140_2022_2063844 crossref_primary_10_1158_2159_8290_CD_20_0215 crossref_primary_10_1159_000538753 crossref_primary_10_1080_14737140_2021_1851200 crossref_primary_10_1016_j_jtocrr_2022_100432 crossref_primary_10_2147_OTT_S272197 crossref_primary_10_3389_fpubh_2021_764977 crossref_primary_10_1016_j_breast_2025_104488 crossref_primary_10_1007_s12282_021_01303_3 crossref_primary_10_1177_03008916251345409 crossref_primary_10_3390_cancers15082194 crossref_primary_10_1007_s12254_021_00722_4 crossref_primary_10_1080_17425255_2023_2197589 crossref_primary_10_1038_s41589_023_01430_2 crossref_primary_10_1111_ajco_13881 crossref_primary_10_1016_j_ejca_2021_11_021 crossref_primary_10_3390_gidisord3010001 crossref_primary_10_3390_medicina60122069 crossref_primary_10_1002_elsc_202000027 crossref_primary_10_1016_j_xphs_2024_10_002 crossref_primary_10_1002_cam4_7256 crossref_primary_10_1016_j_currproblcancer_2021_100795 crossref_primary_10_1111_his_14770 crossref_primary_10_1016_j_bulcan_2021_05_001 crossref_primary_10_1016_j_currproblcancer_2021_100799 crossref_primary_10_1038_s41523_024_00711_w crossref_primary_10_3390_ph17101338 crossref_primary_10_3389_fonc_2022_1086821 crossref_primary_10_1038_s41523_021_00311_y crossref_primary_10_3390_cancers12113317 crossref_primary_10_1038_s43018_021_00190_z crossref_primary_10_1016_j_bbcan_2023_188991 crossref_primary_10_3389_fphar_2024_1446414 crossref_primary_10_1016_j_ctrv_2024_102853 crossref_primary_10_1002_cbic_202400731 crossref_primary_10_1016_j_medj_2024_08_001 crossref_primary_10_7759_cureus_42116 crossref_primary_10_1007_s00761_020_00724_7 crossref_primary_10_1097_PAI_0000000000001281 crossref_primary_10_1186_s13046_024_03105_9 crossref_primary_10_1186_s13046_022_02476_1 crossref_primary_10_1016_j_breast_2025_104470 crossref_primary_10_1016_j_cpccr_2024_100337 crossref_primary_10_2147_OTT_S357326 crossref_primary_10_1093_neuonc_noae103 crossref_primary_10_1016_j_breast_2023_01_007 crossref_primary_10_3389_fphar_2024_1326296 crossref_primary_10_1111_his_14780 crossref_primary_10_3390_cancers13133126 crossref_primary_10_1016_j_pharmthera_2020_107677
Cites_doi	10.1158/1535-7163.MCT-14-0862 10.1093/ajcp/aqz061 10.1158/1538-7445.SABCS18-P6-17-06 10.2307/2530286 10.1200/JCO.2019.37.15_suppl.1002 10.1158/1535-7163.MCT-17-0403 10.1158/1538-7445.SABCS18-P6-17-10 10.1158/0008-5472.CAN-16-3127 10.1016/S1470-2045(19)30088-9 10.1248/cpb.c18-00744 10.1016/j.ejca.2008.10.026 10.1056/NEJMoa1413513 10.1002/prca.201300105 10.1002/pro.2666 10.3121/cmr.2008.825 10.1126/science.3798106 10.1200/JCO.2019.37.15_suppl.1000 10.1111/cas.12966 10.1093/annonc/mdj057 10.1158/1538-7445.SABCS18-P6-17-02 10.1056/NEJMoa1209124 10.1016/S1470-2045(19)30097-X 10.1200/JCO.2019.37.15_suppl.1020 10.1016/S1470-2045(17)30604-6 10.1016/S1470-2045(14)70178-0 10.1200/JCO.2009.23.2025 10.1158/1078-0432.CCR-15-2822 10.1186/bcr3621 10.1371/journal.pone.0112136
ContentType	Journal Article
Contributor	Crook, Timothy Lee, Keun Seok Goksel, Musaberk Jamet, Claire Teixeira, Luis Curigliano, Giuseppe Redfern, Charles Benoit, You Schmid, Peter Ito, Yoshinori Modi, Shanu Fukui, Jami Yousif Ali, Haythem Gonzalez Farre, Xavier Delgado Mingorance, Ignacio Kim, Jee Hyun Gianni, Luca Tamura, Kenji Cazzaniga, Marina Park, Kyong Hwa Hayashi, Naoki Perez Garcia, Jose Manuel Jacot, William Fernandez Abad, Maria Richards, Donald Saura, Cristina Aogi, Kenjiro Park, Yeon Hee Wildiers, Hans Park, Haeseong Dyar, Stephen Rugo, Hope Roylance, Rebecca Andre, Fabrice Swart, Rachel Hall, Peter Iwasa, Tsutomu Vazquez, Silvia Mahtani, Reshma Sohn, Joo Hyuk Baciuchka-Palmaro, Marjorie Bianchi, Giulia Gavila Gregori, Joaquin Canon, Jean-Luc Kim, Sung-Bae Chae, Yee Soo Charif, Mahmoud Matrana, Marc Sagara, Yasuaki Taguchi, Julie Denduluri, Neelima Assikis, Vasileios Rasheed, Amir Abdul Wynendaele, Wim W Chu, David Raymond, Jane Krop, Ian Perrin, Christophe Wagemans, Jill Mukohara, Toru Hurvitz, Sara Jerusalem, Guy Tokunaga, Eriko Takano, Toshimi Curtit, Elsa Ruiz-Borrego, Man
Contributor_xml	– sequence: 1 givenname: Hans surname: Wildiers fullname: Wildiers, Hans – sequence: 2 givenname: Jean-Luc surname: Canon fullname: Canon, Jean-Luc – sequence: 3 givenname: Guy surname: Jerusalem fullname: Jerusalem, Guy – sequence: 4 givenname: Wim W surname: Wynendaele fullname: Wynendaele, Wim W – sequence: 5 givenname: Jill surname: Wagemans fullname: Wagemans, Jill – sequence: 6 givenname: Luis surname: Teixeira fullname: Teixeira, Luis – sequence: 7 givenname: William surname: Jacot fullname: Jacot, William – sequence: 8 givenname: Marjorie surname: Baciuchka-Palmaro fullname: Baciuchka-Palmaro, Marjorie – sequence: 9 givenname: You surname: Benoit fullname: Benoit, You – sequence: 10 givenname: Fabrice surname: Andre fullname: Andre, Fabrice – sequence: 11 givenname: Christophe surname: Perrin fullname: Perrin, Christophe – sequence: 12 givenname: Claire surname: Jamet fullname: Jamet, Claire – sequence: 13 givenname: Elsa surname: Curtit fullname: Curtit, Elsa – sequence: 14 givenname: Julien surname: Grenier fullname: Grenier, Julien – sequence: 15 givenname: Marina surname: Cazzaniga fullname: Cazzaniga, Marina – sequence: 16 givenname: Luca surname: Gianni fullname: Gianni, Luca – sequence: 17 givenname: Giuseppe surname: Curigliano fullname: Curigliano, Giuseppe – sequence: 18 givenname: Giulia surname: Bianchi fullname: Bianchi, Giulia – sequence: 19 givenname: Toru surname: Mukohara fullname: Mukohara, Toru – sequence: 20 givenname: Kenji surname: Tamura fullname: Tamura, Kenji – sequence: 21 givenname: Yoshinori surname: Ito fullname: Ito, Yoshinori – sequence: 22 givenname: Hiroji surname: Iwata fullname: Iwata, Hiroji – sequence: 23 givenname: Tsutomu surname: Iwasa fullname: Iwasa, Tsutomu – sequence: 24 givenname: Yasuaki surname: Sagara fullname: Sagara, Yasuaki – sequence: 25 givenname: Toshimi surname: Takano fullname: Takano, Toshimi – sequence: 26 givenname: Toshinari surname: Yamashita fullname: Yamashita, Toshinari – sequence: 27 givenname: Kenjiro surname: Aogi fullname: Aogi, Kenjiro – sequence: 28 givenname: Eriko surname: Tokunaga fullname: Tokunaga, Eriko – sequence: 29 givenname: Naoki surname: Hayashi fullname: Hayashi, Naoki – sequence: 30 givenname: Seock-Ah surname: Im fullname: Im, Seock-Ah – sequence: 31 givenname: Yeon Hee surname: Park fullname: Park, Yeon Hee – sequence: 32 givenname: Jee Hyun surname: Kim fullname: Kim, Jee Hyun – sequence: 33 givenname: Sung-Bae surname: Kim fullname: Kim, Sung-Bae – sequence: 34 givenname: Joo Hyuk surname: Sohn fullname: Sohn, Joo Hyuk – sequence: 35 givenname: Keun Seok surname: Lee fullname: Lee, Keun Seok – sequence: 36 givenname: Kyong Hwa surname: Park fullname: Park, Kyong Hwa – sequence: 37 givenname: Yee Soo surname: Chae fullname: Chae, Yee Soo – sequence: 38 givenname: Manuel surname: Ruiz-Borrego fullname: Ruiz-Borrego, Manuel – sequence: 39 givenname: Xavier surname: Gonzalez Farre fullname: Gonzalez Farre, Xavier – sequence: 40 givenname: Ignacio surname: Delgado Mingorance fullname: Delgado Mingorance, Ignacio – sequence: 41 givenname: Jose Manuel surname: Perez Garcia fullname: Perez Garcia, Jose Manuel – sequence: 42 givenname: Cristina surname: Saura fullname: Saura, Cristina – sequence: 43 givenname: Maria surname: Fernandez Abad fullname: Fernandez Abad, Maria – sequence: 44 givenname: Silvia surname: Vazquez fullname: Vazquez, Silvia – sequence: 45 givenname: Joaquin surname: Gavila Gregori fullname: Gavila Gregori, Joaquin – sequence: 46 givenname: Srinivisan surname: Madhusudan fullname: Madhusudan, Srinivisan – sequence: 47 givenname: Timothy surname: Crook fullname: Crook, Timothy – sequence: 48 givenname: Peter surname: Schmid fullname: Schmid, Peter – sequence: 49 givenname: Peter surname: Hall fullname: Hall, Peter – sequence: 50 givenname: Rebecca surname: Roylance fullname: Roylance, Rebecca – sequence: 51 givenname: Grace surname: Wang fullname: Wang, Grace – sequence: 52 givenname: Ian surname: Krop fullname: Krop, Ian – sequence: 53 givenname: Reshma surname: Mahtani fullname: Mahtani, Reshma – sequence: 54 givenname: Shanu surname: Modi fullname: Modi, Shanu – sequence: 55 givenname: Haeseong surname: Park fullname: Park, Haeseong – sequence: 56 givenname: Jane surname: Raymond fullname: Raymond, Jane – sequence: 57 givenname: Charles surname: Redfern fullname: Redfern, Charles – sequence: 58 givenname: Rashmi surname: Murthy fullname: Murthy, Rashmi – sequence: 59 givenname: Omkar surname: Marathe fullname: Marathe, Omkar – sequence: 60 givenname: Musaberk surname: Goksel fullname: Goksel, Musaberk – sequence: 61 givenname: Amir Abdul surname: Rasheed fullname: Rasheed, Amir Abdul – sequence: 62 givenname: Haythem surname: Yousif Ali fullname: Yousif Ali, Haythem – sequence: 63 givenname: David surname: Chu fullname: Chu, David – sequence: 64 givenname: Jami surname: Fukui fullname: Fukui, Jami – sequence: 65 givenname: Adam surname: Brufsky fullname: Brufsky, Adam – sequence: 66 givenname: Mahmoud surname: Charif fullname: Charif, Mahmoud – sequence: 67 givenname: Julie surname: Taguchi fullname: Taguchi, Julie – sequence: 68 givenname: Donald surname: Richards fullname: Richards, Donald – sequence: 69 givenname: Rachel surname: Swart fullname: Swart, Rachel – sequence: 70 givenname: Cynthia surname: Osborne fullname: Osborne, Cynthia – sequence: 71 givenname: Stephen surname: Dyar fullname: Dyar, Stephen – sequence: 72 givenname: Sara surname: Hurvitz fullname: Hurvitz, Sara – sequence: 73 givenname: Vasileios surname: Assikis fullname: Assikis, Vasileios – sequence: 74 givenname: Hope surname: Rugo fullname: Rugo, Hope – sequence: 75 givenname: Neelima surname: Denduluri fullname: Denduluri, Neelima – sequence: 76 givenname: Marc surname: Matrana fullname: Matrana, Marc
Copyright	Copyright © 2019 Massachusetts Medical Society. All rights reserved. Copyright © 2019 Massachusetts Medical Society.
Copyright_xml	– notice: Copyright © 2019 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2019 Massachusetts Medical Society.
CorporateAuthor	DESTINY-Breast01 Investigators
CorporateAuthor_xml	– name: DESTINY-Breast01 Investigators
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM
DOI	10.1056/NEJMoa1914510
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Database eLibrary Download PDF from ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection New England Journal of Medicine ProQuest Biological Science Collection Consumer Health Database Healthcare Administration Database Medical Database Psychology Database ProQuest Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic
DatabaseTitleList	ProQuest One Psychology MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1533-4406
EndPage	621
ExternalDocumentID	PMC7458671 31825192 10_1056_NEJMoa1914510 NJ202002133820706
Genre	Original Article Multicenter Study Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	- 0R 0WA 123 186 1VV 29N 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ADBBV ADBIT ADCBC AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ACKOT ACPFK ADRHT ADUKH AERZD AFFHD AGHSJ BYPQX CCPQU CITATION H13 HF~ HMCUK HZ~ N4W PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM AFOSN ALIPV CGR CUY CVF ECM EIF NPM R.3 UIG VXZ YIF YIN Z5M 7XB BEC K0Y MBDVC PKEHL Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c511t-5dea9c7fd7ccea2e9f5437810734105b237b8453c0c2035510d927ba416bf72a3
IEDL.DBID	DCD
ISICitedReferencesCount	1468
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000515383300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0028-4793 1533-4406
IngestDate	Tue Nov 04 02:00:59 EST 2025 Fri Sep 05 08:02:03 EDT 2025 Sat Nov 29 14:51:57 EST 2025 Wed Feb 19 02:31:19 EST 2025 Tue Nov 18 19:58:40 EST 2025 Sat Nov 29 03:02:05 EST 2025 Tue Dec 21 14:38:57 EST 2021
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Language	English
License	http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2019 Massachusetts Medical Society.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c511t-5dea9c7fd7ccea2e9f5437810734105b237b8453c0c2035510d927ba416bf72a3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://www.nejm.org/doi/pdf/10.1056/NEJMoa1914510?articleTools=true
PMID	31825192
PQID	2354260748
PQPubID	40644
PageCount	12
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7458671 proquest_miscellaneous_2324917712 proquest_journals_2354260748 pubmed_primary_31825192 crossref_citationtrail_10_1056_NEJMoa1914510 crossref_primary_10_1056_NEJMoa1914510 mms_nejm_10_1056_NEJMoa1914510
PublicationCentury	2000
PublicationDate	2020-02-13
PublicationDateYYYYMMDD	2020-02-13
PublicationDate_xml	– month: 02 year: 2020 text: 2020-02-13 day: 13
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Boston
PublicationTitle	The New England journal of medicine
PublicationTitleAlternate	N Engl J Med
PublicationYear	2020
Publisher	Massachusetts Medical Society
Publisher_xml	– name: Massachusetts Medical Society
References	Swain, SM, Baselga, J, Kim, S-B (r004) 2015; 372 Brookmeyer, R, Crowley, J (r021) 1982; 38 Gonzalez-Angulo, AM, Litton, JK, Broglio, KR (r001) 2009; 27 Aggarwal, N, Sloane, BF (r012) 2014; 8 Marcoux, J, Champion, T, Colas, O (r028) 2015; 24 Onitilo, AA, Engel, JM, Greenlee, RT, Mukesh, BN (r002) 2009; 7 Rugo, HS, Im, S-A, Write, GLS (r009) 2019; 37 r023 Barok, M, Joensuu, H, Isola, J (r024) 2014; 16 Shitara, K, Iwata, H, Takahashi, S (r033) 2019; 20 r018 r019 r036 Dimopoulou, I, Bamias, A, Lyberopoulos, P, Dimopoulos, MA (r035) 2006; 17 Lin, L, Sirohi, D, Coleman, JF, Gulbahce, HE (r022) 2019; 152 Nakada, T, Sugihara, K, Jikoh, T, Abe, Y, Agatsuma, T (r014) 2019; 67 Swain, SM, Miles, D, Kim, S-B (r005) 2019; 15 Doi, T, Shitara, K, Naito, Y (r011) 2017; 18 Sung, M, Tan, X, Lu, B (r027) 2018; 17 Loganzo, F, Tan, X, Sung, M (r025) 2015; 14 Ogitani, Y, Aida, T, Hagihara, K (r015) 2016; 22 r031 r032 r034 r030 r029 r008 Saura, C, Oliveira, M, Feng, Y-H (r010) 2019; 37 Eisenhauer, EA, Therasse, P, Bogaerts, J (r020) 2009; 45 Ruan, J, Zheng, H, Fu, W, Zhao, P, Su, N, Luo, R (r013) 2014; 9 Ogitani, Y, Hagihara, K, Oitate, M, Naito, H, Agatsuma, T (r016) 2016; 107 Krop, IE, Kim, S-B, González-Martín, A (r007) 2014; 15 Tamura, K, Tsurutani, J, Takahashi, S (r017) 2019; 20 Ríos-Luci, C, García-Alonso, S, Díaz-Rodríguez, E (r026) 2017; 77 Verma, S, Miles, D, Gianni, L (r006) 2012; 367 Slamon, DJ, Clark, GM, Wong, SG, Levin, WJ, Ullrich, A, McGuire, WL (r003) 1987; 235 e_1_3_4_3_2 e_1_3_4_2_2 e_1_3_4_9_2 e_1_3_4_8_2 e_1_3_4_7_2 e_1_3_4_6_2 e_1_3_4_5_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_23_2 e_1_3_4_20_2 e_1_3_4_21_2 e_1_3_4_26_2 e_1_3_4_27_2 e_1_3_4_24_2 e_1_3_4_25_2 e_1_3_4_28_2 e_1_3_4_29_2 e_1_3_4_30_2 e_1_3_4_11_2 e_1_3_4_34_2 e_1_3_4_12_2 e_1_3_4_33_2 e_1_3_4_32_2 e_1_3_4_10_2 e_1_3_4_31_2 e_1_3_4_15_2 e_1_3_4_16_2 e_1_3_4_37_2 e_1_3_4_13_2 e_1_3_4_36_2 e_1_3_4_14_2 e_1_3_4_35_2 e_1_3_4_19_2 e_1_3_4_17_2 e_1_3_4_18_2 31900443 - Nat Rev Clin Oncol. 2020 Mar;17(3):133 32053305 - N Engl J Med. 2020 Feb 13;382(7):669-671
References_xml	– volume: 17 start-page: 372 year: 2006 end-page: 379 ident: r035 article-title: Pulmonary toxicity from novel antineoplastic agents. publication-title: Ann Oncol – volume: 367 start-page: 1783 year: 2012 end-page: 1791 ident: r006 article-title: Trastuzumab emtansine for HER2-positive advanced breast cancer. publication-title: N Engl J Med – ident: r034 – volume: 18 start-page: 1512 year: 2017 end-page: 1522 ident: r011 article-title: Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. publication-title: Lancet Oncol – volume: 24 start-page: 1210 year: 2015 end-page: 1223 ident: r028 article-title: Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. publication-title: Protein Sci – volume: 20 start-page: 827 year: 2019 end-page: 836 ident: r033 article-title: Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. publication-title: Lancet Oncol – volume: 37 start-page: 1000 year: 2019 end-page: 1000 ident: r009 article-title: SOPHIA primary analysis: a phase 3 study of margetuximab + chemotherapy versus trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies. ;:Suppl publication-title: J Clin Oncol – volume: 372 start-page: 724 year: 2015 end-page: 734 ident: r004 article-title: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. publication-title: N Engl J Med – volume: 15 start-page: 1020 year: 2019 end-page: 1020 ident: r005 article-title: End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). ;:Suppl publication-title: J Clin Oncol – ident: r036 article-title: Powell CA, Camidge DR, Gemma A, et al. P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with topoisomerase I inhibitor payload. Presented at the 2018 San Antonio Breast Cancer Symposium, San Antonio, TX, December 4–8, 2018 – volume: 67 start-page: 173 year: 2019 end-page: 185 ident: r014 article-title: The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. publication-title: Chem Pharm Bull (Tokyo) – volume: 16 start-page: 209 year: 2014 end-page: 209 ident: r024 article-title: Trastuzumab emtansine: mechanisms of action and drug resistance. publication-title: Breast Cancer Res – ident: r019 article-title: Modi S, Tsurutani J, Takahashi S, et al. Safety and efficacy results from a phase 1 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2 expressing metastatic breast cancers. Presented at the 2017 San Antonio Breast Cancer Symposium, San Antonio, TX, December 5–9, 2017 – volume: 77 start-page: 4639 year: 2017 end-page: 4651 ident: r026 article-title: Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. publication-title: Cancer Res – volume: 17 start-page: 243 year: 2018 end-page: 253 ident: r027 article-title: Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). publication-title: Mol Cancer Ther – volume: 15 start-page: 689 year: 2014 end-page: 699 ident: r007 article-title: Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. publication-title: Lancet Oncol – ident: r032 – volume: 152 start-page: 479 year: 2019 end-page: 485 ident: r022 article-title: American Society of Clinical Oncology/College of American Pathologists 2018 focused update of breast cancer HER2 FISH testing guidelines: results from a national reference laboratory. publication-title: Am J Clin Pathol – ident: r030 – volume: 27 start-page: 5700 year: 2009 end-page: 5706 ident: r001 article-title: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. publication-title: J Clin Oncol – volume: 7 start-page: 4 year: 2009 end-page: 13 ident: r002 article-title: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. publication-title: Clin Med Res – volume: 107 start-page: 1039 year: 2016 end-page: 1046 ident: r016 article-title: Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. publication-title: Cancer Sci – volume: 38 start-page: 29 year: 1982 end-page: 41 ident: r021 article-title: A confidence interval for the median survival time. publication-title: Biometrics – ident: r023 article-title: Tamura K, Modi S, Tsurutani J, et al. Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: observed clinical data and exposure-response analyses. Presented at the 2018 San Antonio Breast Cancer Symposium, San Antonio, TX, December 4–8, 2018 – ident: r018 article-title: Modi S, Tsurutani J, Tamura K, et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: updated results of a large phase 1 study. Presented at the 2018 San Antonio Breast Cancer Symposium, San Antonio, TX, December 4–8, 2018 – ident: r029 article-title: Herceptin: summary of product characteristics. Welwyn Garden City, United Kingdom: Roche Registration, 2010 – volume: 9 start-page: e112136 issue: 11 year: 2014 end-page: e112136 ident: r013 article-title: Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients. publication-title: PLoS One – volume: 22 start-page: 5097 year: 2016 end-page: 5108 ident: r015 article-title: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. publication-title: Clin Cancer Res – volume: 37 start-page: 1002 year: 2019 end-page: 1002 ident: r010 article-title: Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial. ;:Suppl publication-title: J Clin Oncol – volume: 8 start-page: 427 year: 2014 end-page: 437 ident: r012 article-title: Cathepsin B: multiple roles in cancer. publication-title: Proteomics Clin Appl – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: r020 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). publication-title: Eur J Cancer – ident: r031 article-title: Perjeta: summary of product characteristics. Welwyn Garden City, United Kingdom: Roche Registration. 2013 – ident: r008 article-title: National Comprehensive Cancer Network. Breast cancer (version 2). 2019 ( https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf ) – volume: 20 start-page: 816 year: 2019 end-page: 826 ident: r017 article-title: Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. publication-title: Lancet Oncol – volume: 14 start-page: 952 year: 2015 end-page: 963 ident: r025 article-title: Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. publication-title: Mol Cancer Ther – volume: 235 start-page: 177 year: 1987 end-page: 182 ident: r003 article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. publication-title: Science – ident: e_1_3_4_26_2 doi: 10.1158/1535-7163.MCT-14-0862 – ident: e_1_3_4_23_2 doi: 10.1093/ajcp/aqz061 – ident: e_1_3_4_37_2 doi: 10.1158/1538-7445.SABCS18-P6-17-06 – ident: e_1_3_4_20_2 – ident: e_1_3_4_9_2 – ident: e_1_3_4_22_2 doi: 10.2307/2530286 – ident: e_1_3_4_31_2 – ident: e_1_3_4_11_2 doi: 10.1200/JCO.2019.37.15_suppl.1002 – ident: e_1_3_4_28_2 doi: 10.1158/1535-7163.MCT-17-0403 – ident: e_1_3_4_24_2 doi: 10.1158/1538-7445.SABCS18-P6-17-10 – ident: e_1_3_4_27_2 doi: 10.1158/0008-5472.CAN-16-3127 – ident: e_1_3_4_34_2 doi: 10.1016/S1470-2045(19)30088-9 – ident: e_1_3_4_15_2 doi: 10.1248/cpb.c18-00744 – ident: e_1_3_4_21_2 doi: 10.1016/j.ejca.2008.10.026 – ident: e_1_3_4_30_2 – ident: e_1_3_4_5_2 doi: 10.1056/NEJMoa1413513 – ident: e_1_3_4_13_2 doi: 10.1002/prca.201300105 – ident: e_1_3_4_29_2 doi: 10.1002/pro.2666 – ident: e_1_3_4_3_2 doi: 10.3121/cmr.2008.825 – ident: e_1_3_4_33_2 – ident: e_1_3_4_4_2 doi: 10.1126/science.3798106 – ident: e_1_3_4_10_2 doi: 10.1200/JCO.2019.37.15_suppl.1000 – ident: e_1_3_4_17_2 doi: 10.1111/cas.12966 – ident: e_1_3_4_36_2 doi: 10.1093/annonc/mdj057 – ident: e_1_3_4_19_2 doi: 10.1158/1538-7445.SABCS18-P6-17-02 – ident: e_1_3_4_35_2 – ident: e_1_3_4_7_2 doi: 10.1056/NEJMoa1209124 – ident: e_1_3_4_18_2 doi: 10.1016/S1470-2045(19)30097-X – ident: e_1_3_4_6_2 doi: 10.1200/JCO.2019.37.15_suppl.1020 – ident: e_1_3_4_12_2 doi: 10.1016/S1470-2045(17)30604-6 – ident: e_1_3_4_32_2 – ident: e_1_3_4_8_2 doi: 10.1016/S1470-2045(14)70178-0 – ident: e_1_3_4_2_2 doi: 10.1200/JCO.2009.23.2025 – ident: e_1_3_4_16_2 doi: 10.1158/1078-0432.CCR-15-2822 – ident: e_1_3_4_25_2 doi: 10.1186/bcr3621 – ident: e_1_3_4_14_2 doi: 10.1371/journal.pone.0112136 – reference: 31900443 - Nat Rev Clin Oncol. 2020 Mar;17(3):133 – reference: 32053305 - N Engl J Med. 2020 Feb 13;382(7):669-671
SSID	ssj0000149
Score	2.737314
Snippet	In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had... Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable... BackgroundTrastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a...
SourceID	pubmedcentral proquest pubmed crossref mms
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	610
SubjectTerms	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Body weight Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Confidence intervals Consolidation Chemotherapy Cytotoxicity DNA topoisomerase Drug dosages Epidermal growth factor ErbB-2 protein Female Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunotherapy Intention to Treat Analysis Kaplan-Meier Estimate Lung diseases Lung Diseases, Interstitial - chemically induced Metastases Metastasis Middle Aged Monoclonal antibodies Myelosuppression Nausea Patients Progression-Free Survival Receptor, ErbB-2 - analysis Receptor, ErbB-2 - antagonists & inhibitors Targeted cancer therapy Trastuzumab Tumors
SummonAdditionalLinks	– databaseName: Science Database dbid: M2P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NTxsxEB0VWiEu0JavFIpcCfWERdZex7unik_lAChCtOK2mvV6RVCygewGCX49no0Tkqr0wtlz2PWMPc-e5zcAe8aoGCNscY3K8BAN8jQ2mmshqYwlQ1OzCf-c68vL6OYm7vgLt9LTKid7Yr1RZwNDd-QHQioSU9dh9Ov-gVPXKKqu-hYaC_DRIZuAKF0XojMjH-Xhr79B8hqbLucfUKf5AZK4maLHszM5aaHfL_8FN_9mTc6kobPV9_7AZ1jxAJQdjiPmC3ywxVdYuvAl9jVou-xVVqPnUR9TdmKHI5J5xYJ1C0ZyT0SZ7T2xa8KaNmPt0yvBOzXx69GyI2K4V-yYImm4Dr_PTq-P29y3W-DGoa6Kq8yic1OeaWMsChvnKpQ6cudDSVzQVEidRqGSpmlE08GUoJnFQqfoIF2aa4FyAxaLQWG3gOlYoEv8rZz0vEyapbFtocwzg5HWQYAN2J9MeGK8Fjm1xOgldU1ctZI5_zTg59T8fizC8ZbhrvNeUti7_lsGOxPnJH6xlsmrZxrwYzrslhnVTrCwbmITAp7uZKsD0YDNcRxMP8Vti_T-143ouQiZGpCE9_xI0b2tpbx1qEhg8Nv_P2sblgUd86kPjdyBxWo4st_hk3msuuVwt475FyfTB3c priority: 102 providerName: ProQuest
Title	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
URI	https://nejm.org/doi/full/10.1056/NEJMoa1914510 https://www.ncbi.nlm.nih.gov/pubmed/31825192 https://www.proquest.com/docview/2354260748 https://www.proquest.com/docview/2324917712 https://pubmed.ncbi.nlm.nih.gov/PMC7458671
Volume	382
WOSCitedRecordID	wos000515383300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVBGY databaseName: New England Journal of Medicine Current customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwEB7tAyEuvB-FpTIS4kS0jR13kiPbdtUDLVFVVr1FE8fRFm2zqE1Xgl-Px02rLbBCXL6LJ5LlmYnHnvE3AO-N0QnF1A2QtAkiMhTkicEApeI0loqMrya8-IzjcTybJekBnG7fwlT228In8Nmj-QZ62x3-lHvDXxPTkWl-UnXMtsZm3O_1b_FFNfFuc2XUkGr-8fneJnS4WKz-Fl_-XiZ5a985f_TfM34MD5sQU3za2MQTOLDVU7g_apLoz2Do9qdVvf65XlAu-na5ZiJXqsS8EkzoxEWxVz_ElKNJW4jhYCKD1Jd23VhxxjXsteixrSyfw9fzwbQ3DJqGCoFxcVUd6MKSU0RZoDGWpE1KHSmM3QlQcbVnLhXmcaSV6RjZcYFI2CkSiTm5oC0vUZJ6AUfVdWVfgcBEktvauyUzdpm8yBPbJVUWhmLEMKQWfNyucGYatnFuenGV-ay37mZ7q9OCDzvx7xuajbsE205dGS_6XQInW01mjTuuMqk0M_FjFLfg3W7YORJnR6iybmEzDi3d2RVD2YKXG8XvpuJ-fPzC143gnknsBJike3-kml96sm6MNFMIvv7XvN_AA8lHee41o07gqF6u7Vu4Z27q-WrZhkOcXDDO0GPsMO6FbTg-G4zTSdu7gcNRZ-JxyihHHr94TBkx_QWC1wG4
linkProvider	Massachusetts Medical Society
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3fb9MwED5tA8FexoCNdWzDSLAnrLV2XCcPCMF-qNO6qkJl2ltwHEcUrelo0qHxR_E3cpcmXYvY3vbAs0-RY5_vPtufvwN4Y60KjG-aXBtluWes4VFgNddC0jWW9GzBJjxr607HPz8Pugvwu3oLQ7TKKiYWgToeWjoj3xNSkZi69vwPlz84VY2i29WqhMbELU7c9U_csmXvjw9wft8KcXTY22_xsqoAtwgucq5iZ7A3SaytdUa4IFGe1D5ugyRRHiMhdeR7Stq6FXXMxo16HAgdGUQuUaKFkfjdRXjgkbIYUQVFd0auqoTb5YlVqemJGGOPKtsPDYmpKXqsO5MDFweD7F_w9m-W5kzaO3ryvw3YKqyUAJt9nKyIp7Dg0mfw6LSkEDyHFmbnLB__Gg9MxA7caEwytiZl_ZSRnBVRgi-uWY-wtItZ6_Cz4N2C2Hbl2Cdi8Odsn1bKaA2-3Mt_rMNSOkzdBjAdCIPAppmQXpmN4ihwTSOT2Bpf60bD1OBdNcGhLbXWqeTHRVjc-atmOOcPNdidml9OREZuM9xBbwlT931wm8FW5QxhGYyy8MYTavB62oxhhO6GTOpwYEMC1rhz1w1RgxcTv5t2BcM-vW_GFj3nkVMDkiifb0n73wqpcu0pElDcvLtbr-Bxq3faDtvHnZOXsCzoSINq7sgtWMpHY7cND-1V3s9GO8V6Y_D1vv31D56oYrI
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1db9MwFL3aBpp44fujMIaRgCestnZcJw8Iwbqq07aqmgbaW-Y4jiha09GkQ-On8eu4N3VKixhve-DZVuTYx77H9vG5AK-sVZEJTYdroywPjDU8iazmWki6xpKBrdSEnw_0YBCenETDNfhZv4UhWWW9JlYLdTqxdEbeFFKRmboOwmbmZRHDbu_9-TdOGaToprVOpzGHyL67_I7bt-LdXhfH-rUQvd3jnT73GQa4RaJRcpU6gy3LUm2tM8JFmQqkDnFLJEn-mAipkzBQ0rasaGFkbrfSSOjEIItJMi2MxO-uww0dKEG-_YetoyXrKk-9_emV9_dEvtGkLPcTQ8Zqih7uLsXD9fG4-BvV_VOxuRQCe3f-5867C7c98WYf5jPlHqy5_D5sHnppwQPoY9QuytmP2dgkrOumM7K3NTkb5YxsrkgqfHbJjolju5T1d48EH1aCtwvHPpKyv2Q7NIOmD-HTtfzHI9jIJ7l7AkxHwiDh6WTkY2aTNIlcx8gstSbUut02DXhbD3ZsvQc7pQI5iystgOrEK9howJtF9fO5-chVFbcROXHuvo6vqrBVAyP2i1QR_0ZFA14uinF5oTsjkzvs2JgIN-7odVs04PEcg4umYDigd89YolfQuahA1uWrJfnoS2VhjjOGjBWf_rtZL2ATYRof7A32n8EtQScdlIpHbsFGOZ2553DTXpSjYrpdTT0Gp9cN11-4S2t1
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trastuzumab+Deruxtecan+in+Previously+Treated+HER2-Positive+Breast+Cancer&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Modi%2C+S.&rft.au=Saura%2C+C.&rft.au=Yamashita%2C+T.&rft.au=Park%2C+Y.H.&rft.date=2020-02-13&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=382&rft.issue=7&rft.spage=610&rft.epage=621&rft_id=info:doi/10.1056%2FNEJMoa1914510&rft_id=info%3Apmid%2F31825192&rft.externalDocID=PMC7458671
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon